Aurum Revista Multidisciplinar · Oct 19, 2026
GLP-1 RECEPTOR AGONISTS AND MUSCLE MASS LOSS: IMPLICATIONS FOR MULTIPROFESSIONAL CARE
By Kikuda RN, da Silva RP, Firmo LR et al.
Glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide and tirzepatide, have transformed the treatment of obesity. They produce weight loss previously seen almost exclusively after bariatric surgery. Part of this weight, however, is lean mass. Concern regarding skeletal musculature has grown alongside the popularity of these drugs. Based on a narrative literature review, this study analyzes the evidence on muscle mass loss associated with these pharmaceuticals and discusses its implications for multiprofessional care. The search encompassed the PubMed/MEDLINE, SciELO, and Google Scholar databases, prioritizing randomized clinical trials, meta-analyses, and consensus statements published between 2013 and 2025. In trials using dual-energy X-ray absorptiometry, lean mass accounted for one-fourth to two-fifths of the weight lost. This proportion does not differ substantially from that observed in other forms of weight loss, but the absolute volume is greater. Clinical risk depends on the patient's profile. It is of greater concern in older adults, in individuals with sarcopenic obesity, and in users without professional follow-up. Three measures share consensus: periodic assessment of strength and body composition, adequate protein intake, and supervised resistance exercise. The safe use of these drugs therefore requires a coordinated team. Within it, nursing occupies a central role in screening, health education, and timely referral.